Keyword: Allergan

Joining other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 jobs in Japan in R&D and sales and marketing.

The FDA has OK’d the Daewoong manufacturing plant that will make Evolus’ Botox rival but rejected Evolus' biologic over its manufacturing design.

Billionaire David Tepper has permission to make an activist run at Allergan. Will he use it—and if so, how?

Retail pharmacies accuse Allergan of misrepresenting the facts to gain new patents on its $1.4 billion eye drug, putting off cheap generics.

Allergan and Ironwood want to help people talk about their guts with their doctors—specifically, their possible IBS symptoms.

Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.

Rita Luthra, M.D., was convicted Monday in a Warner marketing scheme—and in more evidence that it's the cover-up that gets you, for lying to investigators.

Competition to Allergan’s Botox is coming, and hoping to get out in front of it, the company's latest ads urge would-be users to ask for it by name.

Allergan may be facing investor pressure to sell some businesses—and boost its share price—but the company managed to beat the Street's Q1 estimates.

Investors aren’t happy with the steps Allergan has taken to try to remedy its share-price slump—and they’re calling on outsiders to help stir things up.